ArticleOncotarget2017
Interleukin-27 polymorphisms are associated with premature coronary artery disease and metabolic parameters in the Mexican population: the genetics of atherosclerotic disease (GEA) Mexican study.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Article
- Prognostic Impact of Interleukin-27 in Peripheral Artery Disease.Life (Basel, Switzerland) · 2025Article
- Recent Insights Into Targeting Interleukin-27 in Coronary Artery Disease.Journal of cardiovascular translational research · 2025Review
- A Plasma Extracellular Vesicle-Derived microRNA Signature as a Potential Biomarker for Subclinical Coronary Atherosclerosis.International journal of molecular sciences · 2025Article
- Article
- Exploring the Involvement of New Members of the Interleukin Family in Cardiovascular Disease.Current cardiology reviews · 2025Review
- Article
- Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation?Frontiers in immunology · 2024Review
- DNA Methylation of the IL-17A Gene Promoter Is Associated with Subclinical Atherosclerosis and Coronary Artery Disease: The Genetics of Atherosclerotic Disease Mexican Study.Current issues in molecular biology · 2023Article
- Association between interleukin-27 gene polymorphisms andInnate immunity · 2023Article
- Osteopontin Gene Polymorphisms Are Associated with Cardiovascular Risk Factors in Patients with Premature Coronary Artery Disease.Biomedicines · 2021Article
- Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity.Life sciences · 2021Article
- Association of theDiagnostics (Basel, Switzerland) · 2021Article
- IL-30Experimental & molecular medicine · 2021Review
- Analysis for interaction between interleukin-35 genes polymorphisms and risk factors on susceptibility to coronary heart disease in the Chinese Han population.BMC cardiovascular disorders · 2021Article
- The IL-6 rs1800795 and rs1800796 polymorphisms are associated with coronary artery disease risk.Journal of cellular and molecular medicine · 2020Article
- Common Variants inBiomolecules · 2020Article
- Roles and Mechanisms of Interleukin-12 Family Members in Cardiovascular Diseases: Opportunities and Challenges.Frontiers in pharmacology · 2020Review
- Association of interleukin-27 gene polymorphisms with susceptibility to HIV infection and disease progression.Journal of cellular and molecular medicine · 2019Article
- Association of common polymorphisms in theArchives of medical science : AMS · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies suggest an important role of Interleukin-27 in the development of atherosclerosis. The aim of this study was to establish whether the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.